Research programme: selective androgen receptor modulators - GTx

Drug Profile

Research programme: selective androgen receptor modulators - GTx

Alternative Names: Andromustine; GTx 026; GTx-027; Libidarine; Prostarine

Latest Information Update: 11 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GTx; Merck & Co
  • Developer GTx
  • Class Azasteroids; Benzamides; Small molecules
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Duchenne muscular dystrophy; Muscular atrophy

Most Recent Events

  • 03 May 2017 Preclinical trials in Duchenne muscular dystrophy in USA before May 2017 (unspecified route)
  • 03 May 2017 Pharmacodynamics data from a preclinical study in Duchenne muscular dystrophy released by GTx
  • 24 Feb 2016 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top